Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1208
Shown on this page
12
Current sort
Recently updated
Campus scope
Columbia University Irving Medical Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Columbia University Irving Medical Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 469–480 of 1,208 matching trials with a site at Columbia University Irving Medical Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

NCT07142252
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Recruiting Not applicable Interventional

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

NCT05655325
Status at this site: Recruiting
View directory record Official record
Conditions
Mild Cognitive Impairment, Chronic Kidney Diseases
Interventions
Home-based walking exercise, Attention control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

NCT07408258
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ONC-783
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Recruiting Phase 3 Interventional

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

NCT06399692
Status at this site: Recruiting
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
18
States / cities
Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The EBC Recovery Study

NCT04712591
Status at this site: Recruiting
View directory record Official record
Conditions
Traumatic Brain Injury, Intracerebral Haemorrhage, Subarachnoid Haemorrhagic Stroke
Interventions
Auditory stimuli
Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Active, not recruiting Phase 1 Interventional

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

NCT03006172
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer, Solid Tumor
Interventions
Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

NCT07670156
Site status not listed — check the official record
View directory record Official record
Conditions
JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
Lisa Satter
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

NCT03122522
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
ipilimumab, nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
13
States / cities
Hartford, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Active, not recruiting Phase 3 Interventional

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927
Site status not listed — check the official record
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate
Interventions
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Active, not recruiting No phase listed Observational

Genentech Validation Tool for Pulmonary Fibrosis

NCT04676594
Site status not listed — check the official record
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
400 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 12:51 PM EDT
Active, not recruiting No phase listed Observational

Surveillance HeartCare® Outcomes Registry

NCT03695601
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Standard of Care
Other
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 12:51 PM EDT

About this Columbia University Irving Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.